Skip to main content

Table 3 Changes in outcome measures (week 0 vs. week 8, week 0 vs. week 20) after treatment completion in the four groups

From: Factors contributing to cognitive improvement effects of acupuncture in patients with mild cognitive impairment: a pilot randomized controlled trial

Groups

Dependent variables

Week 0 (M±SD)

Week 8 (M±SD)

Week 20 (M±SD)

Difference (W8–W0)

Z (p)a

Difference (W20–W0)

Z (p)a

x2 (p)b

BA group (n=8)

MoCA-K

19.63 ±1.51

25.75 ±1.75

25.75 ±2.82

6.13±1.81

−2.54 (0.011)

6.13±3.00

−2.53 (0.012)

12.80 (0.002)

ADAS-K-cog

12.13 ±5.59

5.75 ±2.38

4.63±3.25

−6.38±5.71

−2.32 (0.021)

−7.50±5.37

−2.53 (0.012)

9.75 (0.008)

CES-D

15.63 ±5.88

10.25 ±4.03

10.63 ±5.78

−5.38 ±5.37

−2.31 (0.021)

−5.00 ±7.67

−1.61 (0.108)

4.35 (0.114)

K-ADL

7.00 ±0.00

7.00 ±0.00

7.00 ±0.00

0.00±0.00

0.00 (1.000)

0.00±0.00

0.00 (1.000)

0.00 (1.000)

K-IADL

10.75±0.89

10.13 ±0.35

11.00±1.41

−0.63 ±1.06

−1.52 (0.129)

0.25±1.83

−0.34 (0.732)

3.39 (0.183)

EQ-5D-5L

6.75 ±1.28

5.88 ±1.13

5.88 ±0.64

−0.88 ±0.64

−2.33 (0.020)

−0.88±1.13

−1.90 (0.058)

7.15 (0.028)

AS group (n=8)

MoCA-K

20.88 ±1.36

24.38 ±3.25

25.00 ±3.38

3.50±2.98

−2.21 (0.027)

4.13±3.36

−2.21 (0.027)

10.18 (0.006)

ADAS-K-cog

7.00 ±2.83

4.50 ±1.93

3.38 ±1.77

−2.50±3.16

−1.90 (0.058)

−3.63±2.83

−2.21 (0.027)

7.64 (0.022)

CES-D

15.13 ±6.42

9.50 ±6.91

13.38 ±9.38

−5.63 ±7.19

−2.00 (0.046)

−1.75 ±9.10

−0.73 (0.465)

4.36 (0.113)

K-ADL

7.00 ±0.00

7.00 ±0.00

7.00 ±0.00

0.00.±0.00

0.00 (1.000)

0.00.±0.00

0.00 (1.000)

0.00 (1.00)

K-IADL

11.00 ±1.20

10.63±1.06

10.75±1.39

−0.38±0.52

−1.73 (0.083)

−0.25±0.89

−0.81 (0.414)

2.36 (0.307)

EQ-5D-5L

5.75 ±0.87

5.75 ±1.17

5.50 ±1.07

0.00±0.54

0.00 (1.000)

−0.25±0.71

−1.00 (0.317)

2.00 (0.368)

ND group (n=8)

MoCA-K

19.38 ±2.13

21.75 ±3.11

23.13 ±3.87

2.38±2.45

−2.02 (0.043)

3.75±3.33

−2.02 (0.043)

9.58(0.008)

ADAS-K-cog

10.13 ±4.26

8.75 ±4.74

7.75 ±5.15

−1.38±3.85

−0.92 (0.357)

−2.38±2.62

−1.84 (0.066)

3.44 (0.179)

CES-D

15.25 ±7.07

12.50 ±3.59

15.63 ±5.90

−2.75 ±7.15

−0.94 (0.345)

0.38±2.88

−0.27 (0.786)

2.80 (0.247)

K-ADL

7.38 ±0.74

7.25 ±0.71

7.50 ±0.93

−0.13±0.35

−1.00 (0.317)

0.13±0.35

−1.00 (0.317)

2.00 (0.368)

K-IADL

11.88±3.76

12.00 ±3.78

12.13±3.72

0.13 ±0.35

−1.00 (0.317)

0.25±0.46

−1.41 (0.157)

3.00 (0.223)

EQ-5D-5L

6.63 ±1.60

6.13±1.36

5.88 ±1.46

−0.50 ±0.76

−1.63 (0.102)

−0.75±1.49

−1.30 (0.194)

2.38 (0.305)

EA group (n=8)

MoCA-K

20.63 ±2.07

22.50 ±2.73

23.25 ±3.28

1.88±2.10

−2.04 (0.041)

2.63±2.62

−2.00 (0.046)

5.48 (0.061)

ADAS-K-cog

9.13 ±2.85

7.25 ±2.92

5.38 ±3.70

−1.88±2.10

−2.04 (0.041)

−3.75±2.38

−2.26 (0.024)

11.00 (0.004)

CES-D

15.50 ±11.48

11.38 ±9.01

10.75 ±8.62

−4.13 ±6.40

−1.58 (0.114)

−4.75 ±4.30

−2.21 (0.027)

4.33 (0.142)

K-ADL

7.00 ±0.00

7.00 ±0.00

7.00 ±0.00

0.00.±0.00

0.00 (1.000)

0.00.±0.00

0.00 (1.000)

0.00 (1.000)

K-IADL

10.25±0.46

10.13 ±0.35

10.13±0.35

−0.13±0.64

−0.58 (0.564)

−0.13±0.64

−0.58 (0.564)

0.50 (0.779)

EQ-5D-5L

6.13 ±0.84

5.63 ±0.74

5.50 ±0.76

−0.50±0.93

−1.41 (0.157)

−0.63±0.74

−1.89 (0.059)

5.20 (0.074)

  1. aWilcoxon signed-rank test; brepeated-measures ANOVA (Friedman test)